CN1160070C - A pharmaceutical composition containing kynurbenine and thymine or tryptopham and thymine - Google Patents
A pharmaceutical composition containing kynurbenine and thymine or tryptopham and thymine Download PDFInfo
- Publication number
- CN1160070C CN1160070C CNB988011271A CN98801127A CN1160070C CN 1160070 C CN1160070 C CN 1160070C CN B988011271 A CNB988011271 A CN B988011271A CN 98801127 A CN98801127 A CN 98801127A CN 1160070 C CN1160070 C CN 1160070C
- Authority
- CN
- China
- Prior art keywords
- kynurenin
- gram
- compositions
- pharmaceutical composition
- dissolved
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Abstract
A pharmaceutical composition for the treatment of malignant neoplasms and immunosuppressive deficiencies and its method of production, the active ingredients of said composition being DL-kinurenine, [2-amine-3-(2-aminebenzene) propionic acid] associated with tymine, [2,1 dihydroxy-5-methyl-pyrimidine; 5-methyluracil].
Description
Field of the present invention
The present invention relates to a kind of pharmaceutical composition that is used for the treatment of malignant tumor and immunosuppressant defective, by in cell, mainly be in the cell of those unordered breedings, rebulid the biochemically balanced disease for the treatment of, and relate to the manufacture method of aforementioned pharmaceutical compositions.
Background of invention
At present, by the biochemical research of pair cell, known several dependence traditional treatment means control method for cancer has been used to make a kind of pharmaceutical composition, and this pharmaceutical composition generates the essential amino acids of (benzoic genesis) by benzoic acid and nitrogenous pyrimidine bases derivant is formed.Clinical experiment is verified, and it has the effect that suppresses the unordered breeding of tumor cell.
Of the present invention open
Therefore, first purpose of the present invention is the medicine agent shape that allows by physiology with following ingredient: the DL-kynurenin, and [2-amino-3-(2-aminobenzene) propanoic acid] and thymus pyrimidine, [2,1-dihydroxy-5-methyl-pyrimidine; Methyl uracil] use the essential amino acids that benzoic acid generates and the curative effect of nitrogenous pyrimidine bases isoreactivity composition.
Another object of the present invention provides a kind of method of making pharmaceutical composition, this pharmaceutical composition is prepared as follows, preferably about 50 ℃, restrain with 50ml dissolved in distilled water 1.5-6.0, preferred 3-4 gram DL-kynurenin and 1.2-7.0 gram, preferred 2.5-3.5 gram thymus pyrimidine is made neutral stabilizing solution by adding an amount of potassium hydroxide or sodium hydroxide, its pH value is about 5.6 to 9.0, and preferred 6.8 to 7.3.
Consider that the DL-kynurenin is the end product that anthranil transforms in the biochemical reaction, comprise the tryptophan that is better than kynurenin in the reaction, verified not affecting the treatment with tryptophan replacement kynurenin in required pharmaceutical composition is possible.In pharmaceutical composition, be feasible in original ratio coupling tryptophan [(R)-2-amino-3-(indole-3-propionic acids)] and thymus pyrimidine.
The material of mentioning in the aforementioned pharmaceutical compositions can be with its active ingredient with distilled water diluting or make encapsulated powder and be used for oral.Can make a kind of new drug that is used for the treatment of the biochemistry disorder of in all cancerous cell and immunosuppressant defective, finding thus.
In the presence of enzyme system, occur in the biochemical reaction between the DNA and RNA upper amino acid and nitrogenous base functional group in the cell by observing, several forms damages of finding the chromosome structure that some are caused by hydrolysis or external mutation reagent, deamidization and alkylating agent can obtain repairing (Ames, 1979,204:587-593; Cairns, 1975,233:64-78; With Goodman and Gilman, 1987).We have invented a pharmaceutical formulation, comprising aminoacid that generates from benzoic acid and nitrogenous pyrimidine bases, this medicine is in cell, in the presence of carboxylase, can produce two kinds of influences to DNA and RNA, just, in and the formate that produces when irregular mitosis takes place of chromosome structure and eliminate and be accompanied by the energy that is used to form tumor cell that oxygen evolution produces.
This process is called catacholase, can stop the energy that causes by oxygen to discharge and finish the neutralization of formate, rebuild bridging (Lawitscka with DNA chromosome deoxynucleoside, DadosInformativos de Pesquisa (research information data Research InformativeData), 1960).There is defective in tumor cell on the ribonuclease of purine in the cell mitogen process.This failure that forms at purine makes cell develop into cancerous cell.
We know, the informational molecule that nucleic acid is that control cellular metabolism basic process, macromole are synthetic, cell differentiation and genetic factor transmit, this new product can act directly on cell interior (Valeriote and Santelli, 1984,107-132).
Product of the present invention can be made powder or liquid preparation.As powder, it is wrapped makes capsule with harmless carrier, and as liquid preparation, it is that pH is neutral stable, aqueous solution.
Product of the present invention is made up of DL-kynurenin and nitrogenous pyrimidine bases thymus pyrimidine, and it can make powder or liquid preparation.
For obtaining the curative effect to the tumor cell expection, the maximal dose of recommendation is the DL-kynurenin of 275 mg/day and the thymus pyrimidine of 250 mg/day, per 8 hours oral administrations, and the plasma concentration of active component can remain on not toxigenous level in the component.Recommend to use 100-1, the DL-kynurenin and the 100-1 of 500 mg/day, the dosage of the thymus pyrimidine of 400 mg/day is to obtain the curative effect to malignant tumor.
The medicine that the present invention mentions can be used as the cytothesis agent and is used for malignant tumor and immunosuppressant defective.Its powder can add in the supplementary, is used for tumor resection postoperative patient's rehabilitation and immunodeficiency patient's diet.This medicine is harmless, does not have contraindication, does not cause side effect and untoward reaction when correctly using.Effect duration is not seen the change of its active component physicochemical property during this period for from producing at 24 months on date.No matter capsule or liquid preparation, this medicine all answer lucifuge, be Protected from Heat and moistureproof, and capsule or parcel liquor (sachets) should be stored in the plastic containers, or liquid preparation should be kept in the dark glass container.
The pharmaceutical composition of this medicine is called tk-3, comprises following composition in its liquid preparation:
The DL-kynurenin ... 3.3 gram
Thymus pyrimidine ... 3.0 gram
Potassium hydroxide ... 0.63 gram
Distilled water ... 50 milliliters
In encapsulated powder or parcel liquor:
The DL-kynurenin ... 3.3 gram
Thymus pyrimidine ... 3.0 gram
Kaolin ... 187 grams
Gross weight is that to be equivalent to active component be 250 milligrams to 500 milligrams capsule.
In clinical experiment, research and observation by each active component biological activity in the pharmaceutical composition is transformed can draw such conclusion: replace the DL-kynurenin not influence the curative effect of treatment malignant neoplastic disease man-hour expection by same ratio with tryptophan.
Implement best mode of the present invention
Relevant chromosome structure, DNA and RNA form, and the knowledge of corresponding biochemical reaction can detect us to the defective of purine ribonuclease.Anthranil, the acid of 2-aminotoluene base can be converted into tryptophan and finally be converted into the DL-kynurenin, and the DL-kynurenin is the third level product of these amino acid whose benzoic acid generationizations, utilizes this essential amino acids and nitrogenous pyrimidine bases, thymus pyrimidine [2,4-dihydroxy-5-methyl-pyrimidine; Methyl uracil], find that the cellular biochemical reaction has taken place the nucleoside and the nucleotide of tumor cell under the effect of carboxylase.The purpose of this biochemical reaction that described medicine activity component carries out is to eliminate energy that is produced by oxygen evolution and the formate that neutralizes and produced when unordered cell mitogen takes place tumor cell.In the reaction of this cellular biochemical, the generation of methyl uracil reconstituted cell and the methyl and the formyl of the nitrogenize that produces in the DL-kynurenin scavenger cell mitosis.The methyl uracil reconstruction links with dezyribonucleoside, thereby remove atypical chromosome, because the benzoic acid that they do not follow cell generate rule (benzoic genesis) (Lawitscka, Research Informative Data, 1960-1980); (Jones, 1980,49:253-279); Fraile, 1980,2223-2228; Valerioteand Santelli, 1984,107-132 and Jones, 1979,98:1-8).
Normocellular nucleotide and nucleoside impel cell to carry out mitosis this moment chromosome to be divided into two, and are not like this during the tumor cell mitosis, and its chromosome one is divided into four.
As four DNA of nucleic acid compositions and nitrogenous purine bases (adenine and the guanine of RNA, A and G) and DNA (cytosine and thymus pyrimidine, C and T) and RNA (cytosine and uracil, C and U) pyrimidine bases under the effect of the ribonuclease that influences cell mitogen, form to carry out the mitotic first connection of spindle cell with glucose (pentose).It is cancerous cell that the failure that this purine forms will make cell transformation.Purine can be replaced by ribonucleotide, but is not when cell mitogen.It is irreplaceable when mitosis.Oxidation ribonuclease and deoxyribonuclease are present in the mitotic cell generating process, transform by carboxylase.Deoxyribonuclease is the carrier of cell proliferation and sets up contact between the chromosome by methyl uracil, methyl uracil can generate this reaction of methanoyl kynurenin (oxykinurenine formyl) by kynurenin and formyl remove free oxygen, with in and the energy of cancerous cell.In case rebulid with dezyribonucleoside and to have linked, formyl and methyl nitrogen substituted radical have been removed, cell will be got back to normal mitosis state (Lawitscka, information data, 1960), this link is converted into methyl uracil by uracil and realizes that meanwhile tryptophan is converted into the methanoyl kynurenin in the presence of tryptophan.
Can observe some damage that to revise DNA by the liquid preparation or the powder of the thing that takes this medicine, and these damages cause cell to develop into cancerous cell.
Adult recommended dose is 275 milligrams of DL-kynurenins or tryptophan and 250 mg/day thymus pyrimidines every day.The daily dose of kynurenin can be 100 milligrams and does not wait to 1,500 milligram, preferred 275 mg/day, and this dosage is equally applicable to tryptophan, and the dosage of thymus pyrimidine can be 100 milligrams and does not wait to 1,500 milligram.These recommended dose are applicable to liquid preparation and powder.The normal plasma concentration of tryptophan is 11 ± 2 mg/litre.Can in 24 hours, from urine, drain 50 milligrams of xanthurenic acid (4,8-s after becoming human oral 2 gram tryptophans.Therefore, therapeutic dose should not surpass the upper limit of recommended dose.Overdose can cause the unusual drainage of 2-methyl-3-hydroxy-4-formyl-5-hydroxymethylpyridine. disappearance and xanthurenic acid (4,8-, thereby causes pathology to change, as pyridoxol (vitamin B
6) shortage and the urine indole increase (Hughes, Raine, 1966:399; Guibaut and Froelich, 1973,112; Gehe-Mann, 1959,1:165).
It should be noted that the present invention is not subjected to here institute's restriction of giving an actual example or describe in detail.The result that above-mentioned the application of the invention pharmaceutical composition obtains proves that this medicine is suitable for treating tumor and immunosuppressant defective, and its preparation can make with commercially available raw material easily.
Claims (12)
1. pharmaceutical composition that is used for the treatment of malignant tumor and immunosuppressant defective,
Its feature BeWherein comprise active component DL-kynurenin and thymus pyrimidine.
2. the compositions described in claim 1,
It is characterized in thatReplace the DL-kynurenin with tryptophan.
3. as any described compositions in claim 1 or 2,
It is characterized in thatCompositions is that the alkaline solution with water-bearing media provides.
4. as any described compositions in claim 1 or 2,
It is characterized in thatCompositions is that the form with capsule powder provides.
5. as any described compositions in claim 1 or 2,
It is characterized in thatWherein comprise 1.5-6.0 gram DL-kynurenin and 1.2-7.0 gram thymus pyrimidine, described active component is dissolved in that 50ml is dissolved with an amount of potassium hydroxide so that pH is in 6.5 to 9.0 the aqueous solution.
6. the compositions described in claim 5,
It is characterized in thatWherein comprise 3-4 gram DL-kynurenin and 2.5-3.5 gram thymus pyrimidine, described active component is dissolved in that 50ml is dissolved with an amount of potassium hydroxide so that pH is in 6.8 to 7.3 the aqueous solution.
7. the compositions described in claim 5,
It is characterized in thatReplace potassium hydroxide so that pH is 6.5 to 9.0 with sodium hydroxide.
8. the compositions described in claim 7,
It is characterized in thatReplace potassium hydroxide so that pH is 6.8 to 7.3 with sodium hydroxide.
9. the compositions described in claim 4,
It is characterized in thatDescribed active component is mixed with the Kaolin of q.s to make the capsule from 250 milligrams to 1 gram.
10. make the method for the pharmaceutical composition that is used for the treatment of malignant tumor and immunosuppressant defective,
Its Be characterised in thatComprising the steps: that 1.2-7.0 being restrained thymus pyrimidine and 1.5-6.0 gram DL-kynurenin 50 ℃ of temperature is dissolved in the 50ml distilled water, add an amount of potassium hydroxide or sodium hydroxide, is 6.5 to 9.0 stabilizing solution to make pH value.
11. the method described in claim 10,
It is characterized in thatComprising the steps: 50 ℃ of temperature 2.5 gram thymus pyrimidines and 3-4 gram DL-kynurenins to be dissolved in the 50ml distilled water, add an amount of potassium hydroxide or sodium hydroxide, is 6.8 to 7.3 stabilizing solution to make pH value.
12. the method described in claim 10 or 11,
It is characterized in thatReplace the DL-kynurenin with tryptophan.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| BRPI9702557-7A BR9702557B1 (en) | 1997-07-02 | 1997-07-02 | pharmaceutical composition for the treatment of malignant neoplasms and process for manufacturing a pharmaceutical composition for the treatment of malignant neoplasms. |
| BRPI97025577 | 1997-07-02 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1236315A CN1236315A (en) | 1999-11-24 |
| CN1160070C true CN1160070C (en) | 2004-08-04 |
Family
ID=4067132
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB988011271A Expired - Fee Related CN1160070C (en) | 1997-07-02 | 1998-06-29 | A pharmaceutical composition containing kynurbenine and thymine or tryptopham and thymine |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US6143753A (en) |
| EP (1) | EP0956015B1 (en) |
| CN (1) | CN1160070C (en) |
| AU (1) | AU727853B2 (en) |
| BR (1) | BR9702557B1 (en) |
| DE (1) | DE69822792T2 (en) |
| ES (1) | ES2218835T3 (en) |
| WO (1) | WO1999001125A1 (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7658794B2 (en) | 2000-03-14 | 2010-02-09 | James Hardie Technology Limited | Fiber cement building materials with low density additives |
| US7704316B2 (en) | 2001-03-02 | 2010-04-27 | James Hardie Technology Limited | Coatings for building products and methods of making same |
| US8209927B2 (en) | 2007-12-20 | 2012-07-03 | James Hardie Technology Limited | Structural fiber cement building materials |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1369114A1 (en) * | 2002-06-07 | 2003-12-10 | Peter Priv. Doz. Dr. Terness | Use of tryptophan metabolites as pharmaceutical agents |
| CN102406649A (en) * | 2011-11-15 | 2012-04-11 | 张始状 | Application of five normal basic groups of human body in preparation of medicines for treating tumors |
| CN103720693A (en) * | 2011-11-15 | 2014-04-16 | 张始状 | Application of five normal bases of human body in preparation of medicines for cancer treatment |
| GB201211120D0 (en) * | 2012-06-22 | 2012-08-01 | Bessede Alban | Antagonist to an enzyme and/or a metabolite of the kynurenine pathway |
| GB201322538D0 (en) | 2013-06-21 | 2014-02-05 | Immusmol Sas | Method for detecting small molecules in a sample |
| US20210060158A1 (en) * | 2017-09-19 | 2021-03-04 | Institut Curie | Agonist of aryl hydrocarbon receptor for use in cancer combination therapy |
| BR102019025965A2 (en) * | 2019-12-09 | 2021-06-22 | Cellavit Representação De Produtos Naturais Ltda | vitamin-mineral food supplement |
-
1997
- 1997-07-02 BR BRPI9702557-7A patent/BR9702557B1/en not_active IP Right Cessation
-
1998
- 1998-06-29 ES ES98929162T patent/ES2218835T3/en not_active Expired - Lifetime
- 1998-06-29 US US09/202,126 patent/US6143753A/en not_active Expired - Lifetime
- 1998-06-29 DE DE1998622792 patent/DE69822792T2/en not_active Expired - Lifetime
- 1998-06-29 AU AU79018/98A patent/AU727853B2/en not_active Ceased
- 1998-06-29 CN CNB988011271A patent/CN1160070C/en not_active Expired - Fee Related
- 1998-06-29 WO PCT/BR1998/000045 patent/WO1999001125A1/en active IP Right Grant
- 1998-06-29 EP EP98929162A patent/EP0956015B1/en not_active Expired - Lifetime
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7658794B2 (en) | 2000-03-14 | 2010-02-09 | James Hardie Technology Limited | Fiber cement building materials with low density additives |
| US7727329B2 (en) | 2000-03-14 | 2010-06-01 | James Hardie Technology Limited | Fiber cement building materials with low density additives |
| US8182606B2 (en) | 2000-03-14 | 2012-05-22 | James Hardie Technology Limited | Fiber cement building materials with low density additives |
| US8603239B2 (en) | 2000-03-14 | 2013-12-10 | James Hardie Technology Limited | Fiber cement building materials with low density additives |
| US7704316B2 (en) | 2001-03-02 | 2010-04-27 | James Hardie Technology Limited | Coatings for building products and methods of making same |
| US8209927B2 (en) | 2007-12-20 | 2012-07-03 | James Hardie Technology Limited | Structural fiber cement building materials |
Also Published As
| Publication number | Publication date |
|---|---|
| BR9702557A (en) | 1999-03-09 |
| WO1999001125A1 (en) | 1999-01-14 |
| CN1236315A (en) | 1999-11-24 |
| EP0956015A1 (en) | 1999-11-17 |
| DE69822792T2 (en) | 2005-01-13 |
| ES2218835T3 (en) | 2004-11-16 |
| EP0956015B1 (en) | 2004-03-31 |
| US6143753A (en) | 2000-11-07 |
| BR9702557B1 (en) | 2009-05-05 |
| AU727853B2 (en) | 2001-01-04 |
| AU7901898A (en) | 1999-01-25 |
| DE69822792D1 (en) | 2004-05-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1160070C (en) | A pharmaceutical composition containing kynurbenine and thymine or tryptopham and thymine | |
| Stoeckler et al. | Purine nucleoside phosphorylase. 3. Reversal of purine base specificity by site-directed mutagenesis | |
| KR100225090B1 (en) | Sequence-specific binding polymers for duplex nucleic acids | |
| CN1248686C (en) | Swine growth promoters and method of promoting swine growth | |
| CN1194002C (en) | Shortened-chain polynucleotide and process for the preparation thereof | |
| CN101979645B (en) | Method for preparing adenosylmethionine | |
| WEINSTEIN et al. | Miracil D: An inhibitor of ribonucleic acid synthesis in Bacillus subtilis | |
| Rogers | The components of Life: From nucleic acids to carbohydrates | |
| CN1170366A (en) | Combined use of diclofenac and tribenoside to treat osteoarthritis | |
| CN1341591A (en) | Solution of tetrahydrate N-[ortho-(para-trimethyl acetoxyl benzenesulfonamide) benzoyl] glycine monosodium salt and its medicine | |
| RU2115657C1 (en) | Aqua chelate, method of preparing aqua chelate, method of modulating cell culture characteristics, tissue cultures, single-cell or multi-cell organism cultures, and transport system for transferring metal and organic ligands on cell membrane | |
| CN1944457A (en) | Glutathione calcium chelate and its preparing method, use and composition | |
| CN1372930A (en) | Application of N-acetyl-D-aminoglucose in preparing medicines to prevent and treat sexual disfunction | |
| Tewari | Conformational preferences of modified nucleic acid bases N6‐(Δ2‐isopentenyl) adenine and 2‐methylthio‐N6‐(Δ2‐isopentenyl) adenine by the quantum chemical pcilo calculations | |
| Ogbunude et al. | Adenosine cycle in African trypanosomes | |
| CN1176932C (en) | Zinc fructose-diphosphate and its preparing process and application | |
| Eaton et al. | Examining Basic Chemical Molecules | |
| US7345030B2 (en) | Use of n-acetyl-d-aminoglycosamine in treatment of organ lesions related to toxicosis of drugs or chemicals | |
| CN1494588A (en) | Use of protein histidine phosphatase | |
| Mowbray et al. | The introduction of specific sites for heavy metal binding in a crystalline protein. | |
| CN1748790A (en) | Asparaginase injection its preparing method and use | |
| CN1232256C (en) | Application of N-acetylglucosamine in The preparation of medicine for treating local injure or whole body syndrome due to self immune reaction | |
| CN1297273C (en) | Pyrroloquinoline containing composition for enriching zinc and reducing plumbum | |
| US20060199832A1 (en) | Use of non-immunosupressive pipecolic acid derivatives for inducing chondrogenic differentiation | |
| CN102964442A (en) | Method for preparing polyethylene glycol (PEG) and nerve growth factor (NGF) conjugate |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1061715 Country of ref document: HK |
|
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20040804 Termination date: 20110629 |